An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination With Epirubicin, Cisplatin and Capecitabine (ECX) Versus ECX Alone in Subjects With Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Panitumumab (Primary) ; Capecitabine; Cisplatin; Epirubicin
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms NEOPECX
- 08 Aug 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.
- 31 May 2017 Planned End Date changed from 1 Mar 2017 to 1 Jul 2017.
- 20 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.